Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty

Liu,Ling; Ling,Jing; Ma,Zhenni; Yuan,Quan; Pan,Jun; Yang,Huilin

doi:10.3892/mmr.2014.3041

Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty

Authors:
- Ling Liu
- Jing Ling
- Zhenni Ma
- Quan Yuan
- Jun Pan
- Huilin Yang
View Affiliations

Affiliations: Department of Orthopedics, Clinical Medical Research Center of Jiangsu Province, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215003, P.R. China, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: December 3, 2014 https://doi.org/10.3892/mmr.2014.3041
Pages: 3015-3020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The glycoprotein, von Willebrand factor (VWF) is a carrier protein for factor VIII. When bound to platelets and the extracellular matrix, it promotes aggregation or adhesion of platelets to areas of vascular damage. A disintegrin and metalloproteinase with thrombospondin motif, member 13 (ADAMTS13) cleaves between the tyr1605 and met1606 residues in the central A2 domain of VWF decreasing its activity. The levels of ADAMTS13 and VWF are positively correlated with the risk of developing thrombosis and inversely correlated with the risk of bleeding. A total of 93 patients were observed, who underwent total hip arthroplasty or total knee arthroplasty. Blood samples were collected preoperatively and on postoperative days (PODs) 1, 2, 3, 5 and 7. Plasma levels of the ADAMTS13 antigen were determined using western blotting. The proteolytic activity was validated with the FRETS‑VWF73 assay. VWF:Ag and VWF:RCo activity were measured using an enzyme‑linked immunosorbent assay. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), antithrombin III and plasma fibrinogen levels were measured on a Sysmex® CA500 system with corresponding reagents. D‑dimer levels were measured on a STA‑R fully automated coagulation analyzer. The results demonstrated that, the levels of VWF antigen and activity in the patient increased from postoperative day (POD) 1. By contrast, the level of the ADAMTS13 antigen and its activity in the patients decreased significantly. Starting on POD1, fibrinogen and D‑dimer levels increased. No significant changes were observed in PT, APTT and TT. It was concluded that the ADAMTS13 and VWF levels exhibited a marked association with thrombosis risk. The levels of ADAMTS13 and VWF may be potentially useful as markers for predicting thrombotic complications following arthroplasty and inhibiting the activity of VWF may be a novel prophylaxis to reduce postoperative deep venous thrombosis and pulmonary embolism.

View Figures

View References

1	Anderson JA, Lim W and Weitz JI: Genetics of coagulation: what the cardiologist needs to know. Can J Cardiol. 29:75–88. 2013. View Article : Google Scholar
2	Fisher WD: Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg. 54:344–351. 2011. View Article : Google Scholar : PubMed/NCBI
3	Falck-Ytter Y, Francis CW, Johanson NA, et al; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141(2 Suppl): e278S–e325S. 2012. View Article : Google Scholar : PubMed/NCBI
4	Barrack RL: Current guidelines for total joint VTE prophylaxis: dawn of a new day. J Bone Joint Surg Br. 94:3–7. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sadler JE: von Willebrand factor: two sides of a coin. J Thromb Haemost. 3:1702–1709. 2005. View Article : Google Scholar : PubMed/NCBI
6	Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE and Fujikawa K: Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 276:41059–41063. 2001. View Article : Google Scholar : PubMed/NCBI
7	Porter S, Clark IM, Kevorkian L and Edwards DR: The ADAMTS metalloproteinases. Biochem J. 386:15–27. 2005. View Article : Google Scholar :
8	Tsai HM: Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 87:4235–4244. 1996.PubMed/NCBI
9	Furlan M, Robles R and Lämmle B: Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 87:4223–4234. 1996.PubMed/NCBI
10	Fujikawa K, Suzuki H, McMullen B and Chung D: Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:1662–1666. 2001. View Article : Google Scholar : PubMed/NCBI
11	Koster T, Blann AD, Briet E, Vandenbroucke JP and Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 345:152–155. 1995. View Article : Google Scholar : PubMed/NCBI
12	Tsai AW, Cushman M, Rosamond WD, et al: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 113:636–642. 2002. View Article : Google Scholar : PubMed/NCBI
13	Wang AY, Liu F, Ma ZN, Dong NZ, Zhang JY and Ruan CG: Research on the C-terminal domain of ADAMTS13 regulates its cleaving activity. Zhonghua Xue Ye Xue Za Zhi. 31:830–834. 2010.(In Chinese).
14	Kokame K, Nobe Y, Kokubo Y, Okayama A and Miyata T: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 129:93–100. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ruan CG, Xi XD and Gu JM: Studies on monoclonal antibodies to human von Willebrand factor. Zhonghua Nei Ke Za Zhi. 25:547–550. 1986.(In Chinese).
16	Zhao Y, Gu Y, Ji S, Yang J, Yu Z and Ruan C: Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease. Eur J Haematol. 88:439–445. 2012. View Article : Google Scholar : PubMed/NCBI
17	Clarke MT, Green JS, Harper WM and Gregg PJ: Screening for deep-venous thrombosis after hip and knee replacement without prophylaxis. J Bone Joint Surg Br. 79:787–791. 1997. View Article : Google Scholar : PubMed/NCBI
18	Piovella F, Wang CJ, Lu H, et al: Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 3:2664–2670. 2005. View Article : Google Scholar : PubMed/NCBI
19	Spirin VA, Khomenko NM and Vasil’kov VG: Hemostasis system in patients with bile duct diseases undergoing surgery under peridural anesthesia and neuroleptanalgesia. Anesteziol Reanimatol. 55–57. 1982.(In Russian).
20	Bergqvist D: Assessment of the risk and the prophylaxis of venous thromboembolism in surgical patients. Pathophysiol Haemost Thromb. 33:358–361. 2003. View Article : Google Scholar
21	Müller R and Musikić P: Hemorheology in surgery - a review. Angiology. 38:581–592. 1987. View Article : Google Scholar
22	Picker SM: In-vitro assessment of platelet function. Transfus Apher Sci. 44:305–319. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lindberg F, Rasmussen I, Siegbahn A and Bergqvist D: Coagulation activation after laparoscopic cholecystectomy in spite of thromboembolism prophylaxis. Surg Endosc. 14:858–861. 2000. View Article : Google Scholar : PubMed/NCBI
24	El Kady N, Khedr H, Yosry M and El Mekawi S: Perioperative assessment of coagulation in paediatric neurosurgical patients using thromboelastography. Eur J Anaesthesiol. 26:293–297. 2009. View Article : Google Scholar : PubMed/NCBI
25	Schietroma M, Carlei F, Mownah A, et al: Changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy. Surg Endosc. 18:1090–1096. 2004.PubMed/NCBI
26	Goobie SM, Soriano SG, Zurakowski D, McGowan FX and Rockoff MA: Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph. Anesth Analg. 93:887–892. 2001. View Article : Google Scholar : PubMed/NCBI
27	Lison S, Weiss G, Spannagl M and Heindl B: Postoperative changes in procoagulant factors after major surgery. Blood Coagul Fibrinolysis. 22:190–196. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sadler JE: von Willebrand factor assembly and secretion. J Thromb Haemost. 7(Suppl 1): 24–27. 2009. View Article : Google Scholar : PubMed/NCBI
29	Geerts WH, Pineo GF, Heit JA, et al: Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 126:338S–400S. 2004. View Article : Google Scholar : PubMed/NCBI
30	Zhao YM, Jiang M, Ji SD, et al: Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochem Pharmacol. 85:945–953. 2013. View Article : Google Scholar : PubMed/NCBI